Bonus Biogroup CEO Dr. Shai Meretzky, left, and Vice President of Innovation & Corporate Development Dr. Tomer Bronshtein at the Advanced Therapies Award ceremony in Miami. PHACILITATE.
Bonus Biogroup of Haifa recently became the first Israeli company ever to receive an Advanced Therapies Award, winning in the Cell Therapy Biotech Innovation category.
Bonus Biogroup currently has two groundbreaking products undergoing advanced clinical trials: MesenCure, a cell therapy for treating inflammation and tissue damage, including pneumonia and respiratory distress; and BonoFill, a living human bone graft designed for bone tissue regeneration and rehabilitation.
The award was announced during Advanced Therapies Week, January 16-19, in Miami. The sponsor of the international event, Phacilitate, provides conferences, communities and market intelligence to connect and support professionals in the cell and gene therapy industry.
The judging panel of biotech executives, academics, investors and vendors also bestowed Advanced Therapies Awards on companies including Rocket Pharmaceuticals and Novartis Gene Therapies.
The Bonus Biogroup CEO Dr. Shai Meretzky said the award “is a testament to the international professional acclaim for our extensive journey in cell therapy and tissue engineering, from conception to clinical application. This recognition belongs to our dedicated team, medical partners, and investors, who have unwaveringly supported our vision of providing advanced, safe, and effective treatments for challenging and prevalent medical conditions. We remain committed to leading in biotechnology sciences and developing solutions to improve human health.”
On January 10, Bonus Biogroup announced the awarding of a Japanese patent for its pioneering cell characterization technology, a core component of BonoFill. “This significant patent extends our rights for the exclusive use and commercialization of BonoFill. The patented technology features a unique gene expression profile in bone-forming cells harvested from human adipose tissue and cultivated in an innovative 3-dimensional culture,” said Meretzky as he explained.
“This marks a key milestone in tapping into Japan’s $24 billion market for bone deficiency treatment. Japan’s forward-thinking regulatory landscape aligns perfectly with our innovative products like BonoFill and MesenCure, driving our commitment to lead in advanced therapeutic solutions,” said the group.
In addition to the two products in clinical trials, Bonus Biogroup also maintains a variety of technologies and products in the preclinical development phase.
Produced in association with ISRAEL21c
Get news, handpicked just for you, in your box.
